淋巴瘤患者外周血EB病毒检测及分型的临床意义  

Clinical Significance of Peripheral Blood EBV-DNA Determination and Genotyping in Lymphoma Patients

作　　者：王颖君[1] 巴音 陈秋雨 韩艳秋[2] WANG Ying-Jiun;BA Yin;CHEN Qiu-Yu;HAN Yan-Qiu(Department of Laboratory Medicine,The Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,Inner Mongolia Autonomous Region,China;Department of Hematology,The Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,Inner Mongolia Autonomous Region,China)

机构地区：[1]内蒙古医科大学附属医院检验科,内蒙古呼和浩特010050 [2]内蒙古医科大学附属医院血液科,内蒙古呼和浩特010050

出　　处：《中国实验血液学杂志》2021年第6期1802-1806,共5页Journal of Experimental Hematology

基　　金：内蒙古自治区自然科学基金项目(编号2017MS0889)。

摘　　要：目的:探讨淋巴瘤患者外周血EB病毒(EBV)检测及分型的临床意义。方法:纳入内蒙古地区西部的淋巴瘤患者101例,收集分析患者年龄、性别、淋巴瘤类型、Ann Arbor分期、结外浸润、乳酸脱氢酶等资料。采用荧光定量PCR技术检测101例淋巴瘤患者外周血中EB病毒的含量,并对EB病毒阳性患者进行EB病毒分型检测。分析EB病毒核酸定量与淋巴瘤的临床不良预后因素、近期疗效的关系。结果:EBV-DNA外周血检出率为68.3%(69/101)。淋巴瘤患者不良预后因素分析显示,EBV阳性的淋巴瘤患者较EBV阴性患者拥有更多的不良预后因素,其临床预后较差。在接受4个疗程治疗后,46例B细胞类型非霍奇金淋巴瘤患者中,EB病毒阳性组的总缓解率为60.7%,EB病毒阴性组的总缓解率为88.9%,差异有统计学意义(P<0.05)。19例霍奇金淋巴瘤患者中,EB病毒阳性组的总缓解率为46.2%,EB病毒阴性组的总缓解率为100%,差异有统计学意义(P<0.05)。EB病毒分型结果显示,98.6%(68/69)为2型EB病毒,1.4%(1/69)为1型和2型的混合感染。结论:EB病毒阳性淋巴瘤患者以EBV-2型感染为主。外周血中EB病毒核酸阳性的淋巴瘤患者近期疗效明显差于EB病毒核酸阴性患者。Objective: To explore the clinical significance of Epstein-Barr virus( EBV) detection and classification in peripheral blood of lymphoma patients. Methods: 101 lymphoma patients were enrolled,the clinical characteristics of the patients were collected,including ages,sex,types of lymphoma,Ann Arbor stages,extranodal infiltration and lactate dehyhrogenase. Fluorescent quantitative PCR technology was used to detect the EBV-DNA. Polymerase chain reaction and Agarose gel electrophoresis was used for determination of EB genotyping. The difference between curative effect in EBV-DNA+ and EBV-DNA-patients,the correlation of adverse factors and EBV infection of the patients were analyzed.Results: 68. 3%( 69/101) of the patients showed EBV-DNA positive. EBV-positive lymphoma patients showed more adverse prognostic factors than the patients with EBV-negative,which may lead to poorer disease outcome. Among the46 B-cell non-Hodgkin’s lymphoma patients,the overall response rate of EBV-positive patients( 60. 7%) was lower than EBV-negative patients( 88.9%)( P< 0. 05);For 19 patients with Hodgkin’ s lymphoma,the overall response rate of EBV-positive patients( 46. 2%) was lower than EBV-negative patients( 100%),the differences were statistically significant( P<0.05). Among 69 patients with EBV-infected lymphoma,98.6%( 68/69) showed type-2 EB virus,and1.4%( 1/69) were type-1 and type-2 mixed infections. Conclusion: Most of EBV-positive in lymphoma patients were EBV type 2,patients with EBV-DNA;shows poorer efficacy than EBV-DNA;patients.

关 键 词：淋巴瘤 EB病毒 EBV-DNA 基因分型 

分 类 号：R733.1[医药卫生—肿瘤]